Leigh Calhoun
Nurse Practitioner · Chattanooga, TNNPI 1891058079
Payments from drug & device makers
Across 334 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Optinose US, Inc.$770
- Regeneron Healthcare Solutions, Inc.$655
- Sanofi$380
- Amgen$238
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$1252%
- Food & beverage$6,45297%
- Education$791%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 45 | $1,295 |
| GSK | 74 | $1,033 |
| Optinose US, Inc. | 60 | $770 |
| Regeneron Healthcare Solutions, Inc. | 29 | $655 |
| Sanofi | 16 | $380 |
| Amgen | 12 | $238 |
| Biocryst US Sales Co., LLC | 11 | $237 |
| CSL Behring | 9 | $204 |
| Teva Pharmaceuticals USA, Inc. | 10 | $163 |
| Mylan Specialty L.p. | 10 | $162 |
| Grifols USA, LLC | 7 | $145 |
| Octapharma USA, Inc. | 3 | $145 |
| Genentech USA, Inc. | 7 | $142 |
| Incyte Corporation | 2 | $137 |
| Aimmune Therapeutics, Inc. | 1 | $125 |
| Pfizer | 6 | $119 |
| Verona Pharma, Inc. | 4 | $107 |
| Sanofi-aventis U.S. LLC | 2 | $99 |
| Kaleo, Inc. | 5 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $61 |
| Novartis | 2 | $50 |
| Boehringer Ingelheim | 2 | $47 |
| Cycle Pharmaceuticals Inc | 2 | $42 |
| Ionis Pharmaceuticals, Inc. | 2 | $39 |
| Pharming Healthcare, Inc. | 1 | $28 |
| Alk-abello, Inc | 1 | $25 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $22 |
| Boston Scientific | 1 | $20 |
| AbbVie | 1 | $19 |
| Galderma Laboratories, L.p. | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Insmed, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,656 in reported general payments places this provider in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 136 | $93,076 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 65 | $40,754 |
| OpzeluraRuxolitinib Phosphate | 12 | $22,968 |
| Breo ElliptaFluticasone/Vilanterol | 43 | $19,051 |
| Spiriva RespimatTiotropium Bromide | 15 | $9,533 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $9,492 |
| Arnuity ElliptaFluticasone Furoate | 31 | $7,559 |
| Epinephrine | 29 | $5,119 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $4,510 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 18 | $2,454 |
| Mometasone Furoate | 21 | $2,046 |
| Azelastine Hcl | 45 | $1,682 |
| Montelukast Sodium | 143 | $1,582 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 65 | $1,578 |
| Ipratropium Bromide | 66 | $1,493 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,033 | $119,686210 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,295 | $45,26381 claims |
| Incyte CorporationOpzelura | $137 | $22,96812 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $47 | $19,02527 claims |
| Hikma Pharmaceuticals USAEpinephrine | $14 | $5,11929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Chattanooga
- Cynthia WilsonChattanooga$62K
- Honor HightshueChattanooga$45K
- Amy OttmanChattanooga$32K
- Philip AndrewsChattanooga$18K
- Amberly EllisChattanooga$17K
- Erin StockwellChattanooga$15K
- Teresa DeeseChattanooga$13K
- Jay PassmoreChattanooga$13K
- Amy HatcherMurfreesboro$1.1M
- Karen RodenKnoxville$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.